Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (March 2025)
46 slides from Immatics's investor presentation, Mar 27, 2025
Slide 1: Immatics Corporate Presentation
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 27, 2025
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: Commercializing PRAME cell therapy in 2L cutaneous melanoma
3 Commercializing PRAME cell therapy in 2L cutaneous melanoma Expanding the PRAME commercial opportunity to additional solid cancer types and earlier lines of treatment IMA203 expansion into uveal melanoma through ongoing Phase 1b trial IMA203CD8 GEN2 in PRAME+ solid cancers, starting with gynecolog
Slide 4: Immatics pipeline
4 1 Phase 1a: Dose escalation, Phase 1b: Dose expansion; 2 With or without checkpoint inhibitor (pembrolizumab); 3 mRNA - enabled in vivo expressed TCER® molecules; 4 Immatics’ proprietary ACTallo® platform utilizing Editas’ CRISPR gene editing technology; 2L Melanoma: patients with unresectable or
Slide 5: Immatics' Clinical Portfolio
Immatics’ Clinical Portfolio Clinical Activity 1 P ositi o ni n g Next Expected Mile st o ne Expanding the PRAME cell therapy opportunity to additional solid cancer types beyond melanoma and earlier lines of treatment Data updates on all clinical assets throughout 2025 4 Clinically Active TCR Candid
Slide 6: Breadth of PRAME Commercial Opportunity in Solid Cancers
Breadth of PRAME Commercial Opportunity in Solid Cancers Based on Positive Data and High Unmet Need 6 ~230k addressable PRAME + /HL A - A * 02:0 1 + patients in the US & EU5 Near - T erm Mid - & Long - Term 2L Unresectable or Metastatic Cutaneous Melanoma IMA203 BRAF WT or BRAF mutated Unresectable
Slide 7: Realizing the Multi-Cancer Opportunity of PRAME
Realizing the Multi - Cancer Opportunity of PRAME ACTengine® IMA203 / IMA203CD8 (TCR - T) and TCER® IMA402 (TCR Bispecific) 7 Cancer Cell Death PRAME is one of the most promising and prevalent clinically validated solid tumor targets known to date I n t r o Phase 3 in cut. melanoma and Phase 1b in u
Slide 8: Leadership in the Development of TCR-based Therapies
Leadership in the Development of TCR - based Therapies Two Distinct TCR - based Therapeutic Modalities in Clinical Development 8 I n t r o 1 Target product profile (TPP) in monotherapy in 2L settings at recommended phase 2 dose (“RP2D”). Other factors such as mPFS (median progression free survival)
Slide 9: ACTengine IMA203 – TCR-Based Cell Therapy Targeting PRAME
ACTengine® IMA203 – TCR - Based Cell Therapy Targeting PRAME 9
Slide 10: The ACTengine IMA203 Commercial Opportunity in Melanoma
The ACTengine® IMA203 Commercial Opportunity in Melanoma TCR - Based Cell Therapy Targeting PRAME 10 IMA203 Opportunity ~7.3k addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 ~1.3k addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 All patient numbers refer to PRAME+/HLA - A*
Slide 11: ACTengine IMA203 TCR-T Targeting PRAME in Melanoma
IMA203 Data cut - off Aug 23, 2024 11 SUPRAME Phase 3 trial in 2L cutaneous melanoma actively enrolling patients 1 Includes all benefits of Breakthrough Therapy Designation; * PRAME + /HLA - A*02:01 + addressable patient population, source: Clarivate Disease Landscape and Forecast 2025; CRS: cytokin
Slide 12: IMA203 TCR-T Monotherapy – Patient Journey
ACTengine® IMA203 TCR - T Monotherapy – Patient Journey 12 1 Gragert et al. 2013 and census numbers; HLA - A*02:01 prevalence in Immatics’ clinical trials: US 65% and Germany 55% as of March 2025; 2 30 mg/m 2 Fludarabine and 500 mg/m 2 Cyclophosphamide for 4 days; 3 1m IU daily days 1 - 5 and twice
Slide 13: ACTengine IMA203 TCR-T in Melanoma
ACTengine® IMA203 TCR - T in Melanoma Data cut - off Aug 23, 2024 13 1 All infused patients; *Cutaneous melanoma patients had a median of 2 prior lines of checkpoints; RP2D: recommended phase 2 dose; CPI: Checkpoint inhibitors; EC1: 0.06 - 0.12x10 9 TCR - T cells/m 2 BSA; DL3: 0.2 - 0.48x10 9 TCR -
Slide 14: Most Frequent Adverse Events of IMA203
Data cut - off Aug 23, 2024 14 * One grade 3 CRS only after exploratory second infusion; CRS and ICANS graded by CARTOX criteria (Neelapu et al ., 2019); ICANS: Immune effector cell - associated neurotoxicity syndrome Most Frequent Adverse Events of IMA203 Across All Dose Levels in Phase 1a/b N=70 P
Slide 15: Tolerability Profile of IMA203 Across All Dose Levels
Tolerability Profile of IMA203 Across All Dose Levels in Phase 1a/b All treatment - emergent adverse events (TEAEs) with ≥ Grade 3 regardless of relatedness to study treatment . Adverse events were coded using the Medical Dictionary for Regulatory Activities . Grades were determined according to Nat
Slide 16: Clinical Anti-Tumor Activity of IMA203 Monotherapy in Melanoma
Clinical Anti - Tumor Activity of IMA203 Monotherapy in Melanoma Objective Responses in Heavily Pretreated Patients in Phase 1b (N=28 # ) Data cut - off Aug 23, 2024 16 on g oing # First tumor assessment post infusion pending for two melanoma patients at data - cut; * Maximum change of target lesion
Slide 17: Duration of IMA203 Monotherapy Responses in Melanoma
Duration of IMA203 Monotherapy Responses in Melanoma Durable Responses 2+ Years after Treatment in Heavily Pretreated Patients in Phase 1b (N=28 # ) Ongoing Scans at approximately week 6, month 3 and then every 3 months Data cut - off Aug 23, 2024 17 # First tumor assessment post infusion pending fo
Slide 18: Significant Shift in PFS and OS Between Dose Escalation & Expansion
Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion mPFS of 6 Months and mOS Not Reached in Melanoma Efficacy Population Progression Free Survival Data cut - off Aug 23, 2024 18 Overall Survival Overall survival (OS) and progression - free survival (PFS) censored at data - cut;
Slide 19: IMA203 Phase 1b in Melanoma: Overview of Studies
IMA203 Phase 1b in Melanoma: Overview of Studies PFS and OS Data in Melanoma Cohorts mOS (months) mPFS (months) Prior lines of therapies Melanoma patient population N Phase Drug Product not r e a ched 6.0 4% n=0, 18% n=1, 32% n=2, 29% n=3:, 4% n=4, 11% n=5, 4% n=6 86% received prior CPI (median of 1
Slide 20: Enhanced mPFS of >1 Year in Melanoma Patients with Deep Responses
Enhanced mPFS of >1 Year in Melanoma Patients with Deep Responses N=26 # • 46% (12/26) patients in dose expansion have a deep response (≥50% tumor reduction) • This subgroup of patients has highly medically meaningful mPFS of more than 1 year • Patients with <50% tumor reduction (including tumor siz
Slide 21: SUPRAME: Registration-Enabling Randomized Phase 3 Trial
SUPRAME: Registration - Enabling Randomized Phase 3 Trial Actively Enrolling Patients, ~50 Sites Planned across the US and Europe 21 ACTengine® IMA203 N=180 Investigator’s choice of selected approved treatments N=180 En d poi n ts • Primary Endpoint • PFS, which allows trial readout quicker than ove
Slide 22: Cell Therapy Manufacturing Facility
Cell Therapy Manufacturing Facility To Support IMA203 BLA and Commercialization 22 IMA203 • ~100,000 sq ft state - of - the - art research & GMP manufacturing facility • Modular design for efficient and cost - effective scalability - total of 8 manufacturing suites, plus further expansion space • Ca
Slide 23: ACTengine IMA203CD8 – Expansion Beyond Melanoma
ACTengine® IMA203CD8 – Expansion of the PRAME Commercial Opportunity Beyond Melanoma 23
Slide 24: Expansion of PRAME Commercial Opportunity Beyond Melanoma
Expansion of PRAME Commercial Opportunity Beyond Melanoma Second Generation ACTengine® IMA203CD8 Leveraging CD8 and CD4 T Cells 24 IMA203CD8 Opportunity 2L Solid Tumors All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025; Source: Clarivate Disease Landscape and F
Slide 25: ACTengine IMA203CD8 Summary: Clinical Data & Next Steps
ACTengine® IMA203CD8 TCR - T Targeting PRAME Summary: Clinical Data & Next Steps Data cut - off Sep 30, 2024 25 Dose escalation ongoing to investigate full clinical potential in hard - to - treat solid tumors outside of melanoma IMA203CD8 T ole r ability Manageable tolerability ≥Grade 3 AEs mainly e
Slide 26: Tolerability of IMA203CD8 Monotherapy
Tolerability of IMA203CD8 Monotherapy All ≥Grade 3 Adverse Events (N=44) Data cut - off Sep 30, 2024 26 IMA203CD8 … table continued 100.0 44 Patients with any adverse event 9 .1 4 Immune system disorders 15.9 7 Adverse events of special interest 9 .1 4 Haemophagocytic lymphohistiocytosis 2 13.6 2.3
Slide 27: Clinical Anti-Tumor Activity of IMA203CD8 Monotherapy
Clinical Anti - Tumor Activity of IMA203CD8 Monotherapy (N=41) Ongoing Dose Escalation Data cut - off Sep 30, 2024 27 IMA203CD8 41% (14/34) cORR 9.2 months 2.0+, 23.5+ 13.1 months median DOR (min, max) mFU 10/17 responses ongoing including 3 confirmed responses at 1+ year Deep responses with ≥50% tu
Slide 28: Duration of IMA203CD8 Monotherapy Responses
Duration of IMA203CD8 Monotherapy Responses (N=41) Ongoing Dose Escalation Data cut - off Sep 30, 2024 28 IMA203CD8 1 Metabolic complete response (CR) according to PET - CT 2 Patients off study at data - cut; 3 three patients excluded from tumor shrinkage analysis and figures due to lack of post - t
Slide 29: Opportunity of IMA203CD8 in Medium-Level PRAME Expressing Indications
Opportunity of IMA203CD8 in Medium - Level PRAME Expressing Indications 29 * Patients treated at RP2D during Ph1b with evaluable post baseline assessments at data - cut off IMA203: Aug 23, 2024; BOR: best of response; PD: progressive disease; SD: stable disease; (c)PR: (confirmed) partial response;
Slide 30: TCER IMA402 - Off-the-Shelf TCR Bispecific Targeting PRAME
TCER® IMA402 - Off - the - Shelf TCR Bispecific Targeting PRAME 30
Slide 31: Expansion of the PRAME Commercial Opportunity to 1L Tumors
Expansion of the PRAME Commercial Opportunity to 1L Tumors Off - the - Shelf Biologic Approach to Target First Line Setting 31 IMA402 Opportunity All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025; Source: Clarivate Disease Landscape and Forecast; EU5: France, G
Slide 32: TCER IMA402 Targeting PRAME Summary: Phase 1 Dose Escalation
Cancer Cell TCER® IMA402 Targeting PRAME Summary: Phase 1 Dose Escalation Study 32 Dose escalation in advanced stage indications at higher DLs ongoing T ole r ability Favorable tolerability profile Most common treatment - related AEs are low - grade CRS and transient lymphopenia Early dose escalatio
Slide 33: Phase 1/2 Clinical Trial to Evaluate TCER IMA402
Phase 1/2 Clinical Trial to Evaluate TCER® IMA402 Targeting PRAME 33 IMA402 1 Cutaneous melanoma, uveal melanoma, synovial sarcoma, endometrial cancer, ovarian cancer, squamous non - small cell lung cancer; 2 Step dosing introduced at DL4; Low - dose dexamethasone used as preventive measure for init
Slide 34: IMA402 Demonstrates Favorable Tolerability in N=33 Patients
34 IMA402 Demonstrates Favorable Tolerability in N=33 Patients Most Frequent Related AEs were Lymphopenia and CRS ≥ Grade 3 All Grades TEAEs, n [%] 17 [52] 33 [100] Any 15 [45] 32 [97] Treatment - related ≥ Grade 3 All Grades Treatment - related AEs 1 , n [%] 10 [30] 17 [52] Lymphopenia 1 [3] 16 [48
Slide 35: Early Signs of Clinical Activity Associated with PRAME Expression and Dose
Positive/NT Negative PRAME Status 7+ * 1 - 6 Across DLs Dose Levels 78% 25% 14% Patients with Tumor Shrinkage Early Signs of Clinical Activity Associated with PRAME Expression and IMA402 Dose 35 BOR (RECIST 1.1) Ongoing response / SD (RECIST1.1/ iRECIST) Data cut - off Nov 6, 2024 * Patients who rec
Slide 36: Exemplary Patient Cases Suggesting Dose-Dependent Tumor Response
Exemplary Patient Cases Suggesting Dose - Dependent Tumor Response 36 Data cut - off Nov 6, 2024 BOR: Best Overall Response; SD: Stable Disease; cPR: Confirmed Partial Response; arrow: Ongoing response / stable disease (RECIST 1.1/ iRECIST) Patients with Disease Control (RECIST1.1) at Relevant Doses
Slide 37: TCER IMA401 - Off-the-Shelf TCR Bispecific Targeting MAGEA4/8
TCER® IMA401 - Off - the - Shelf TCR Bispecific Targeting MAGEA4/8 37
Slide 38: The IMA401 Commercial Opportunity in Solid Cancers
The IMA401 Commercial Opportunity in Solid Cancers TCER® IMA401 Targeting MAGEA4/8 38 IMA401 Opportunity 1L Solid Tumors 1 Target prevalence is based on TCGA RNAseq data combined with a proprietary mass spec - guided RNA expression threshold; All patient numbers refer to MAGEA4/8 + /HLA - A*02:01 +
Slide 39: TCER IMA401 Targeting MAGEA4/8 Summary: Phase 1 Dose Escalation
Cancer Cell MAGEA4/8 TCER® IMA401 Targeting MAGEA4/8 Summary: Phase 1 Dose Escalation Study 39 AE: Adverse Event; CRS: Cytokine Release Syndrome; (c)ORR: (confirmed) objective response rate; PR: Partial Response; DCR: disease control rate; CPI: checkpoint inhibitors; q4w: once every four weeks; HNSC
Slide 40: Trial Design – IMA401-101 Phase 1a Dose Escalation
40 180 µg 540 µg 1800 µg 2500 µg Key Eligibility Criteria O b jecti v es Primary: • Determine MTD and/or RP2D Secondary: • Tolerability • Pharmacokinetics • Initial anti - tumor activity • Recurrent and/or refractory solid tumors • HLA - A*02:01 positive • MAGEA4/8 - positive as confirmed by mRNA -
Slide 41: IMA401 Demonstrates Manageable Tolerability in N=35 Patients
41 IMA401 Demonstrates Manageable Tolerability in N=35 Patients Most Frequent Related AEs were Lymphopenia, CRS and Neutropenia ≥ Grade 3 All Grades TEAEs, n [%] 26 [74] 32 [91] Any 19 [54] 28 [80] Treatment - related ≥ Grade 3 All Grades Treatment - related AEs 1 , n [%] 11 [31] 12 [34] Lymphopenia
Slide 42: Objective Responses are Associated with Target Expression
1 Patients in this analysis had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression above indicated MAGEA4/A8 high qPCR threshold (n=17); PD: Progressive disease; PR: Partial response; cPR: confirmed Partial response; SD: Stable disease. Objective Responses are Associated with T
Slide 43: IMA401 Demonstrates Initial Anti-Tumor Activity in Multiple Tumor Types
IMA401 Demonstrates Initial Anti - Tumor Activity in Multiple Tumor Types 43 * Patients in this analysis are part of the efficacy analysis set with at least one post - treatment tumor assessment and had rece ived IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression higher than the MAGEA4/
Slide 44: The Immatics Opportunity
ose immatics The Immatics Opportunity
Slide 45: The Immatics Opportunity: Delivering the Power of T Cells to Cancer Patients
The Immatics Opportunity Delivering the Power of T Cells to Cancer Patients 45 Leveraging 2 TCR modalities to target solid cancers TCR - T cell therapy (ACTengine®) and TCR Bispecifics (TCER®) directed against pHLA targets to address late - and early - stage solid cancers Achieving robust cell thera
Slide 46: Thank you
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Thank you www.immatics.com